NEW YORK, NY — March 22, 2002 — Forest Laboratories, Inc. announced that clinical study results were presented March 20th at the annual meeting of the Anxiety Disorders Association of America (ADAA), including a trial demonstrating that Lexapro (escitalopram oxalate) significantly reduced anxiety in patients with generalized anxiety disorder (GAD) when compared to placebo.
Other research presented at the meeting included a study demonstrating that, when compared to placebo, Lexapro significantly reduced panic symptoms in patients with panic disorder, including panic attack frequency and severity, and a study showing that Lexapro significantly improved symptoms in patients with social anxiety disorder (SAD) as compared to placebo. Lexapro, the single-active isomer of Celexa (citalopram HBr), is an investigational selective serotonin reuptake inhibitor (SSRI).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!